MedTrace Logo

Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

NCT06203236 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-01-12

No results posted yet for this study

Summary

To investigate the effectiveness and feasibility of natriuresis-guided diuretic therapy as a personalized approach to managing acute heart failure in patients with underlying chronic kidney disease and its effect on short term outcomes.

Conditions

  • Acute Heart Failure
  • Chronic Kidney Diseases

Interventions

DRUG

Furosemide 20 MG

1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide. 2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.

OTHER

diuretic therapy

diuretic therapy

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Salah Eldin Sayed Atta, Supervisor · Assiut University

  • Heba Mahmoud Abdel-Mohsen El-Naggar, Supervisor · Assiut University

  • Mohamed Abdullah Khalifah, Supervisor · South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-03-31
Completion
2025-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203236 on ClinicalTrials.gov